Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time
NCT01611025 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30000
Last updated 2012-06-04
Summary
This is a retrospective, multicentre, observational study to assess the trends in antibiotic utilization and hospital ecology with respect to susceptibility patterns of selected bacterial isolates to the utilized antibiotics.
Conditions
Sponsors & Collaborators
-
Taipei Veterans General Hospital, Taiwan
lead OTHER_GOV
Principal Investigators
-
Fu-Der Wang, M.D. · Taipei Veterans General Hospital, Taiwan
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-06-30
- Completion
- 2013-12-31
More Related Trials
-
Antimicrobial Resistance Rate In Escherichia Coli And Klebsiella Pneumonia : A Retrospective Study
NCT04196387 ·Status: COMPLETED
-
Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales
NCT07160569 ·Status: NOT_YET_RECRUITING
-
Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli
NCT00573235 ·Status: COMPLETED
-
Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae
NCT01138566 ·Status: UNKNOWN
-
Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia
NCT03925402 ·Status: COMPLETED
-
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
NCT00081744 ·Status: COMPLETED ·Phase: PHASE3
-
WGS-guided Tracking and Infection Control Measures of CRKP
NCT04413305 ·Status: UNKNOWN ·Phase: NA
-
An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.
NCT01173068 ·Status: UNKNOWN
-
Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
NCT01297842 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria
NCT03338738 ·Status: COMPLETED ·Phase: NA
-
Clinical and Biological Impact of Gut Microbiota in Adult Patients With Bacteremia During the COVID-19 Pandemic
NCT07183722 ·Status: ACTIVE_NOT_RECRUITING
-
Empirical Antibiotic and Outcome in Community-onset Bacteremia
NCT03765749 ·Status: COMPLETED
-
Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
NCT03357614 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Ertapenem in Beta-lactam Allergic Patients.
NCT01159379 ·Status: UNKNOWN ·Phase: PHASE4
-
Antibiotic-resistant Bacterial Infection of Hepatic Patients
NCT03855709 ·Status: UNKNOWN
-
Detection of Anaerobes in Different Clinicalsamples
NCT03266341 ·Status: UNKNOWN
-
Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics
NCT03967301 ·Status: UNKNOWN ·Phase: NA
-
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
NCT00404625 ·Status: UNKNOWN
-
A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
NCT01721408 ·Status: COMPLETED ·Phase: PHASE4
-
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
NCT00363220 ·Status: COMPLETED
-
A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
NCT00724919 ·Status: COMPLETED
-
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
NCT04516395 ·Status: UNKNOWN ·Phase: NA
-
Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria
NCT05516433 ·Status: RECRUITING
-
Burden of Antibiotic Resistance in Gram-Negative Infections in Dutch Hospitals
NCT02007343 ·Status: COMPLETED
-
Study of Human Microbiota in Healthy and Pathological Conditions
NCT03460392 ·Status: UNKNOWN